Your browser doesn't support javascript.
Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine : A Case-Control Study.
Lai, Francisco Tsz Tsun; Li, Xue; Peng, Kuan; Huang, Lei; Ip, Patrick; Tong, Xinning; Chui, Celine Sze Ling; Wan, Eric Yuk Fai; Wong, Carlos King Ho; Chan, Esther Wai Yin; Siu, David Chung Wah; Wong, Ian Chi Kei.
  • Lai FTT; Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, and Laboratory of Data Discovery for Health (D24H), Hong Kong Science Park, Hong Kong Science and Technology Park, Hong Kong Special Administrative
  • Li X; Department of Medicine and Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, and Laboratory of Data Discovery for Health (D24H), Hong Kong Science Park, Hong Kong Science and Technology Park, Hong
  • Peng K; Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China (K.P., L.H.).
  • Huang L; Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China (K.P., L.H.).
  • Ip P; Department of Paediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China (P.I.).
  • Tong X; Department of Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China (X.T., D.C.W.).
  • Chui CSL; Laboratory of Data Discovery for Health (D24H), Hong Kong Science Park, Hong Kong Science and Technology Park, and the School of Nursing and School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China (C.S.L.).
  • Wan EYF; Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, and Department of Family Medicine and Primary Care, Li Ka Shing Faculty of Medicine, The University of Hong Kong, and Laboratory of Data Discovery for Health (D24H), Hong Kong Science Park, Hong Kong Science a
  • Wong CKH; Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, and Department of Family Medicine and Primary Care, Li Ka Shing Faculty of Medicine, The University of Hong Kong, and Laboratory of Data Discovery for Health (D24H), Hong Kong Science Park, Hong Kong Science a
  • Chan EWY; Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, and Laboratory of Data Discovery for Health (D24H), Hong Kong Science Park, Hong Kong Science and Technology Park, Hong Kong Special Administrative
  • Siu DCW; Department of Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China (X.T., D.C.W.).
  • Wong ICK; Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, and Laboratory of Data Discovery for Health (D24H), Hong Kong Science Park, Hong Kong Science and Technology Park, Hong Kong Special Administrative
Ann Intern Med ; 175(3): 362-370, 2022 03.
Article in English | MEDLINE | ID: covidwho-1818640
ABSTRACT

BACKGROUND:

Case reports of carditis after BNT162b2 vaccination are accruing worldwide.

OBJECTIVE:

To examine the association of BNT162b2 and CoronaVac (Sinovac) vaccination with carditis.

DESIGN:

Case-control study with hospital control participants.

SETTING:

Territory-wide, public health care database with linkage to population-based vaccination records in Hong Kong. PATIENTS Inpatients aged 12 years or older first diagnosed with carditis were selected as case patients. All other hospitalized patients without carditis were treated as control participants. Ten control participants were randomly matched with each case patient by age, sex, and admission date. INTERVENTION Vaccination with BNT162b2 or CoronaVac. MEASUREMENTS Incident diagnosis of carditis based on the International Classification of Diseases, Ninth Revision, and elevated troponin levels.

RESULTS:

A total of 160 case patients and 1533 control participants were included. Incidence of carditis per 100 000 doses of CoronaVac and BNT162b2 administered was estimated to be 0.31 (95% CI, 0.13 to 0.66) and 0.57 (CI, 0.36 to 0.90), respectively. Multivariable analyses showed that recipients of the BNT162b2 vaccine had higher odds of carditis (adjusted odds ratio [OR], 3.57 [CI, 1.93 to 6.60]) than unvaccinated persons. Stratified by sex, the OR was 4.68 (CI, 2.25 to 9.71) for males and 2.22 (CI, 0.57 to 8.69) for females receiving the BNT162b2 vaccine. The ORs for adults and adolescents receiving the BNT162b2 vaccine were 2.41 (CI, 1.18 to 4.90) and 13.79 (CI, 2.86 to 110.38), respectively. Subanalysis showed an OR of 9.29 (CI, 3.94 to 21.91) for myocarditis and 1.06 (CI, 0.35 to 3.22) for pericarditis associated with BNT162b2. The risk was mainly seen after the second dose of BNT162b2 rather than the first. No association between CoronaVac and carditis with a magnitude similar to that for BNT162b2 was seen.

LIMITATION:

Limited sample size, absence of electrocardiography and other clinical investigative data, and unrecorded overseas vaccination exposure.

CONCLUSION:

Despite a low absolute risk, there is an increased risk for carditis associated with BNT162b2 vaccination. This elevated risk should be weighed against the benefits of vaccination. PRIMARY FUNDING SOURCE Health and Medical Research Fund.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / BNT162 Vaccine / Myocarditis Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Adolescent / Adult / Child / Female / Humans / Male Language: English Journal: Ann Intern Med Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / BNT162 Vaccine / Myocarditis Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Adolescent / Adult / Child / Female / Humans / Male Language: English Journal: Ann Intern Med Year: 2022 Document Type: Article